Autolus presents FELIX update: 78% ORR, 40% ongoing remission without SCT, median OS 23.8 months

Autolus Therapeutics plc

ORR 78% (99/127); median EFS 11.9 months, median OS 23.8 months; 12-month OS rate 61.1%.
40% of responders in ongoing remission without SCT or other therapy at median 21.3 months follow-up.
Ongoing CAR T persistence associated with 2.7x lower relapse/death risk vs. loss of persistence.
Consolidative SCT after obe-cel did not appear to improve EFS or OS in responders.
BLA under FDA review with PDUFA target action date November 16, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.